Not to be administered intravascularly. Not to be used for prevention of HFMD caused by other enteroviruses including Coxsackievirus A16. Patients w/ thrombocytopenia or hemorrhagic disease; immunodeficiency disorder or those receiving immunosuppressive therapy; uncontrolled epilepsy or other progressive nervous system disease. Observe patient for at least 30 min after inj. Co-administration w/ Ig (at least 1-mth interval).